ReviewJournal of psychopharmacology (Oxford, England)2013
Amphetamine, past and present--a pharmacological and clinical perspective.
Review in Journal of psychopharmacology (Oxford, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03337646 (A Multi-Center, Open Label, Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder), which is not on this map. Cited by 211 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-Center, Open Label, Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder
Who cites it
211 citing papers in PubMed, 8 syntheses or guidelines pooled it, 605 citations in OpenAlex.
- Effects of EEG neurofeedback in adults with attention-deficit/hyperactivity disorder: a systematic review of randomised and non-randomised studies.Journal of neurodevelopmental disorders · 2026Pooled it
- Cognitive effects of methamphetamine and amphetamine withdrawal in rodents: a systematic review.Frontiers in psychology · 2026Pooled it
- Effect of amphetamines on blood pressure.The Cochrane database of systematic reviews · 2025Pooled it
- Treatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis.JAMA psychiatry · 2024Pooled it
- Amphetamines in child medicine: a review of ClinicalTrials.gov.Frontiers in pharmacology · 2023Pooled it
- A global systematic review and meta-analysis on illicit drug consumption rate through wastewater-based epidemiology.Environmental science and pollution research international · 2020Pooled it
- Amphetamine Use in the Elderly: A Systematic Review of the Literature.Current neuropharmacology · 2020Pooled it
- Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.The Cochrane database of systematic reviews · 2018Pooled it
- Acute methamphetamine and alcohol usage alters gaze behaviour during driving: A randomised, double-blind, placebo-controlled study.Journal of psychopharmacology (Oxford, England) · 2024Trial
- A randomized, double-blind, placebo-controlled trial of ondansetron for the treatment of cocaine use disorder with post hoc pharmacogenetic analysis.Drug and alcohol dependence · 2021Trial
- Acute drug effects differentially predict desire to take dextroamphetamine again for work and recreation.Psychopharmacology · 2021Trial
- Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study.BMJ open · 2021Trial
- Open-label pilot study of lisdexamfetamine for cocaine use disorder.The American journal of drug and alcohol abuse · 2021Trial
- Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies.Neuropsychiatric disease and treatment · 2020Trial
- Effects of Ginkgo biloba extract EGb 761® on cognitive control functions, mental activity of the prefrontal cortex and stress reactivity in elderly adults with subjective memory impairment - a randomized double-blind placebo-controlled trial.Human psychopharmacology · 2016Trial
- Pilot study of the effects of lisdexamfetamine on cocaine use: A randomized, double-blind, placebo-controlled trial.Drug and alcohol dependence · 2015Trial
- The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study.Journal of child and adolescent psychopharmacology · 2015Trial
- Differential and state-dependent effects of the GluN2A-selective positive allosteric modulator GNE-5729 on executive functions.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- The effects of increasing and decreasing dopamine on inhibition of return: a psychopharmacological investigation.Experimental brain research · 2026Article
- Effects of exposure to lisdexamfetamine dimesylate on hepatic parameters of pubertal rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
151 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Amphetamine was discovered over 100 years ago. Since then, it has transformed from a drug that was freely available without prescription as a panacea for a broad range of disorders into a highly restricted Controlled Drug with therapeutic applications restricted to attention deficit hyperactivity disorder (ADHD) and narcolepsy. This review describes the relationship between chemical structure and pharmacology of amphetamine and its congeners. Amphetamine's diverse pharmacological actions translate not only into therapeutic efficacy, but also into the production of adverse events and liability for recreational abuse. Accordingly, the balance of benefit/risk is the key challenge for its clinical use. The review charts advances in pharmaceutical development from the introduction of once-daily formulations of amphetamine through to lisdexamfetamine, which is the first d-amphetamine prodrug approved for the management of ADHD in children, adolescents and adults. The unusual metabolic route for lisdexamfetamine to deliver d-amphetamine makes an important contribution to its pharmacology. How lisdexamfetamine's distinctive pharmacokinetic/pharmacodynamic profile translates into sustained efficacy as a treatment for ADHD and its reduced potential for recreational abuse is also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.